| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTGX | Exit | Protagonist Therapeutics Inc | $0 | – | -32,211 | -100.0% | -0.06% | – |
| BLPH | Exit | Bellerophon Therapeutics | $0 | – | -659,087 | -100.0% | -0.06% | – |
| ETNB | Exit | 89Bio Inc | $0 | – | -41,235 | -100.0% | -0.29% | – |
| MYOV | Exit | Myovant Sciences Ltd | $0 | – | -76,768 | -100.0% | -0.31% | – |
| NXTC | Exit | Nextcure Inc | $0 | – | -36,249 | -100.0% | -0.54% | – |
| MIST | Exit | Milestone Pharmaceuticals Inc | $0 | – | -148,560 | -100.0% | -0.63% | – |
| FTSV | Exit | Forty Seven Inc | $0 | – | -77,714 | -100.0% | -0.81% | – |
| MRNS | Exit | Marinus Pharmaceuticals Inc | $0 | – | -1,486,676 | -100.0% | -0.85% | – |
| ADVM | Exit | Adverum Biotechnologies Inc | $0 | – | -383,620 | -100.0% | -1.16% | – |
| RLMD | Exit | Relmada Therapeutics Inc | $0 | – | -114,876 | -100.0% | -1.18% | – |
| SPRO | Exit | Spero Therapeutics Inc | $0 | – | -474,015 | -100.0% | -1.20% | – |
| MRSN | Exit | Mersana Therapeutics Inc | $0 | – | -922,514 | -100.0% | -1.39% | – |
| OBSV | Exit | Obseva SA | $0 | – | -1,573,639 | -100.0% | -1.58% | – |
| KALV | Exit | Kalvista Pharmaceuticals | $0 | – | -366,268 | -100.0% | -1.72% | – |
| ISEE | Exit | Iveric Bio Inc | $0 | – | -1,004,299 | -100.0% | -2.27% | – |
| SWAV | Exit | Shockwave Medical Inc | $0 | – | -288,838 | -100.0% | -3.34% | – |
| BHVN | Exit | Biohaven Pharmaceuticals | $0 | – | -462,903 | -100.0% | -6.64% | – |
| CNST | Exit | Constellation Pharmaceuticals | $0 | – | -1,500,631 | -100.0% | -18.64% | – |
| AXSM | Exit | Axsome Therapeutics Inc | $0 | – | -785,981 | -100.0% | -21.42% | – |
| TXG | Exit | 10X Genomics Inc. | $0 | – | -1,786,431 | -100.0% | -35.91% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Ascendis Pharma A/S | 16 | Q3 2019 | 18.3% |
| BioCryst Pharmaceuticals Inc | 15 | Q3 2019 | 20.9% |
| Ra Pharmaceuticals | 12 | Q3 2019 | 6.4% |
| Biohaven Pharmaceuticals | 11 | Q4 2019 | 18.1% |
| Obseva SA | 11 | Q4 2019 | 12.2% |
| DBV Technologies | 10 | Q1 2018 | 11.6% |
| Kalvista Pharmaceuticals | 10 | Q4 2019 | 6.4% |
| Bellerophon Therapeutics | 10 | Q4 2019 | 3.0% |
| AveXis Inc | 9 | Q1 2018 | 32.2% |
| Edge Therapeutics Inc | 9 | Q4 2017 | 18.2% |
View VHCP Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-10-26 |
| 4 | 2022-10-20 |
| 4 | 2022-10-17 |
| 4 | 2022-10-11 |
| 4 | 2022-10-06 |
| 4 | 2022-10-03 |
| 4 | 2022-09-28 |
| 4 | 2022-09-07 |
| 4 | 2022-09-01 |
| 4 | 2022-08-02 |
View VHCP Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.